首页> 美国卫生研究院文献>Oncology Letters >MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase
【2h】

MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase

机译:通过直接靶向胸苷酸合酶MicroRNA-330在大肠癌中抑制细胞增殖并增强对5-氟尿嘧啶的化学敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Colorectal cancer (CRC) is the third most common cancer in males and the second most common in females, worldwide. Currently, 5-fluorouracil (5-FU)-mediated chemotherapy is the adjuvant treatment for patients with CRC following surgical resection. However, a number of patients with CRC develop 5-FU resistance, which is a major challenge for the effective treatment of cancer. Therefore, it is important to investigate the molecular mechanisms underlying chemoresistance and the therapeutic treatments that may improve the treatment of CRC. The present study demonstrated that microRNA (miR)-330 was significantly downregulated in CRC tissues and cell lines. Ectopic miR-330 expression decreased cell proliferation and enhanced cell chemosensitivity to 5-FU via the cell apoptosis pathway in CRC. In addition, thymidylate synthase (TYMS) was revealed to be a direct target gene of miR-330 in CRC. Knockdown of TYMS inhibited CRC cell proliferation, and enhanced cell chemosensitivity to 5-FU by promoting cell apoptosis. In conclusion, the results of the present study indicated that miR-330 targeted TYMS to inhibit the proliferation and enhance the chemosensitivity of CRC cells to 5-FU by promoting cell apoptosis. The present study provided important insight into the molecular mechanism underlying 5-FU-mediated chemoresistance and a novel therapeutic strategy for the enhancement of efficacy in CRC treatment.
机译:在世界范围内,结直肠癌(CRC)是男性中排名第三的癌症,女性中排名第二。当前,5-氟尿嘧啶(5-FU)介导的化学疗法是外科切除术后CRC患者的辅助治疗。然而,许多CRC患者产生5-FU抗性,这是有效治疗癌症的主要挑战。因此,重要的是研究化学抗性的分子机制和可能改善CRC治疗的治疗方法。本研究表明,在CRC组织和细胞系中microRNA(miR)-330显着下调。异位miR-330表达通过CRC中的细胞凋亡途径降低细胞增殖并增强对5-FU的细胞化学敏感性。此外,胸苷酸合酶(TYMS)被发现是CRC中miR-330的直接靶基因。敲低TYMS可以抑制CRC细胞增殖,并通过促进细胞凋亡来增强对5-FU的细胞化学敏感性。总之,本研究的结果表明,miR-330靶向TYMS,可通过促进细胞凋亡来抑制CRC的增殖并增强CRC细胞对5-FU的化学敏感性。本研究为5-FU介导的化学抗性的分子机制提供了重要的见识,并为增强CRC治疗的疗效提供了新的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号